Loading...
Loading...
According to Jefferies, Johnson & Johnson's
JNJ Q1:11 results and comments point toward improving pricing, volume, and utilization trends in select divisions.
Jefferies reported that read-through is neutral-to-positive for competing companies in our universe including COV, BCR on the surgical end, and COO on the vision end. "Johnson & Johnson (JNJ, $60.46,
NC) reported Q1:11 revenue of $16.2B (+1.8% y/y operational) and EPS of $1.25 (-3.1% y/y adjusted) versus Street expectations of $15.9B and $1.26. The company raised its EPS guidance to $4.90-$5.00, up from $4.80-$4.90 to reflect F/X impacts, strong pharma performance supported by recent launches, and other operational and capital restructuring benefits. Revised guidance does not include the after-tax gain of $910M realized in the quarter as a result of litigation settlements, nor does it reflect the pending $500M payment from Merck (MRK GR, €67.56, Hold - Holford) as a result of the recent REMICADE settlement.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in